Sanjay Gandhi to Cost-Benefit Analysis
This is a "connection" page, showing publications Sanjay Gandhi has written about Cost-Benefit Analysis.
Connection Strength
0.267
-
Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective. Clin Ther. 2008 Jul; 30(7):1345-57.
Score: 0.074
-
Applegate R, Sacrinty M, Schafer P, Smith J, Gandhi S, Kutcher M, Santos R, Cecile A, Little W. Cost effectiveness of radial access for diagnostic cardiac catheterization and coronary intervention. Catheter Cardiovasc Interv. 2013 Oct 01; 82(4):E375-84.
Score: 0.026
-
Ohsfeldt RL, Olsson AG, Jensen MM, Gandhi SK, Paulsson T. Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial. J Med Econ. 2012; 15(1):125-33.
Score: 0.023
-
Schafer PE, Sacrinty MT, Cohen DJ, Kutcher MA, Gandhi SK, Santos RM, Little WC, Applegate RJ. Cost-effectiveness of drug-eluting stents versus bare metal stents in clinical practice. Circ Cardiovasc Qual Outcomes. 2011 Jul; 4(4):408-15.
Score: 0.023
-
Ohsfeldt RL, Gandhi SK, Smolen LJ, Jensen MM, Fox KM, Gold A, Hsia J. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ. 2010; 13(3):428-37.
Score: 0.021
-
Ohsfeldt RL, Gandhi SK, Fox KM, McKenney JM. Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications. Value Health. 2008 Dec; 11(7):1061-9.
Score: 0.018
-
Suraratdecha C, Ramana CV, Kaipilyawar S, Sivalenka S, Ambatipudi N, Gandhi S, Umashankar K, Cheyne J. Cost and effectiveness analysis of immunization service delivery support in Andhra Pradesh, India. Bull World Health Organ. 2008 Mar; 86(3):221-8.
Score: 0.018
-
Locker GY, Mansel R, Cella D, Dobrez D, Sorensen S, Gandhi SK. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat. 2007 Dec; 106(2):229-38.
Score: 0.017
-
Ohsfeldt RL, Gandhi SK, Fox KM, Stacy TA, McKenney JM. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice. Am J Manag Care. 2006 Nov; 12(15 Suppl):S412-23.
Score: 0.017
-
Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M, Penson D. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? Urology. 2005 Oct; 66(4):835-9.
Score: 0.015
-
Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. J Urol. 2005 Aug; 174(2):547-52; discussion 552.
Score: 0.015